Your browser doesn't support javascript.
Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature.
Aves, Kara-Lee; Janitzek, Christoph M; Fougeroux, Cyrielle E; Theander, Thor G; Sander, Adam F.
  • Aves KL; Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Janitzek CM; Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Fougeroux CE; AdaptVac, Ole Maaløes Vej 3, 2200 Copenhagen, Denmark.
  • Theander TG; Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Sander AF; Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark.
Pharmaceutics ; 14(6)2022 Jun 18.
Article in English | MEDLINE | ID: covidwho-2163552
ABSTRACT
The requirement of an undisrupted cold chain during vaccine distribution is a major economic and logistical challenge limiting global vaccine access. Modular, nanoparticle-based platforms are expected to play an increasingly important role in the development of the next-generation vaccines. However, as with most vaccines, they are dependent on the cold chain in order to maintain stability and efficacy. Therefore, there is a pressing need to develop thermostable formulations that can be stored at ambient temperature for extended periods without the loss of vaccine efficacy. Here, we investigate the compatibility of the Tag/Catcher AP205 capsid virus-like particle (cVLP) vaccine platform with the freeze-drying process. Tag/Catcher cVLPs can be freeze-dried under diverse buffer and excipient conditions while maintaining their original biophysical properties. Additionally, we show that for two model cVLP vaccines, including a clinically tested SARS-CoV-2 vaccine, freeze-drying results in a product that once reconstituted retains the structural integrity and immunogenicity of the original material, even following storage under accelerated heat stress conditions. Furthermore, the freeze-dried SARS-CoV-2 cVLP vaccine is stable for up to 6 months at ambient temperature. Our study offers a potential solution to overcome the current limitations associated with the cold chain and may help minimize the need for low-temperature storage.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Pharmaceutics14061301

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Pharmaceutics14061301